QCT Uses New AMD EPYC™ 7003 Processors to Drive Performance and Value for the Modern Data Center
15.3.2021 18:00:00 EET | Business Wire | Press release
Quanta Cloud Technology (QCT), a global data center solution provider, announced its growing portfolio of Total Cloud Solutions featuring AMD EPYC™ 7003 Series Processors. QCT systems supporting AMD EPYC™ 7003 series processors help their customers adapt to changing business needs, while offering incredible performance with faster time to results.
Among QCT’s Total Cloud Solutions making their debut is the all-new QuantaGrid D43N-3U server which supports the 3rd Gen AMD EPYC™ processors and provides the highest CPU-GPU ratio in the market.
AMD EPYC™ 7003 Series Processors
Based on the “Zen 3” core architecture, the AMD EPYC™ 7003 Series processors drive a new standard for the modern data center with fantastic performance capabilities. Designed to be the world’s highest performance x86 server processor, it helps companies maximize their investments while providing an attractive data center ROI. AMD also continues to drive x86 security innovation with a group of advanced security features and a silicon embedded security subsystem that helps protect a customer’s most valuable asset – their data.
“We designed the EPYC™ 7003 Series processors to give our customers exactly what they said they needed, performance across all workloads and the ability to drive more time to value, right out of the box,” said Ram Peddibhotla, corporate vice president, EPYC product management, AMD. “With leadership architecture, performance, and modern security features, EPYC™ 7003 Series processors are a superior choice and continue to drive the standard for the modern data center.”
QCT QuantaGrid D43N-3U server
The D43N-3U is a dual-socket server designed to support up to 4 double-width or 8 single-width GPU accelerators without any PCIe switch chips. Not only does this reduce the latency between GPU and CPU, but it allows the system to act as a powerhouse for various disciplines - i.e. HPC, weather forecasting, automotive, AI training and inference, graphic rendering, cloud gaming, etc.
“QCT is always looking to deliver products that meet changing workload needs,” said Mike Yang, President of QCT. “With the QuantaGrid D43N-3U, we worked with our strategic partner, AMD, to deliver innovations that combine all the advantages of the 3rd Gen AMD EPYC processors with our comprehensive designs to allow our customers to arm their data center with the resources to drive performance in a consolidated solution.”
QCT is tapping the full functionality of the AMD EPYC™ 7003 Series processors with more compute, more memory, more expansion possibilities, and more bandwidth between nodes to enable businesses with access to more data resulting in faster answers. Organizations of all sizes can benefit from the innovation and performance breakthroughs EPYC™ 7003 Series processors deliver. QCT also offers other QuantaGrid models that support AMD EPYC™ processors for HPC and more.
For more details visit https://go.qct.io/EPYC.
About Quanta Cloud Technology (QCT)
QCT is a global data center solution provider that combines the efficiency of hyperscale hardware with infrastructure software from a diversity of industry leaders to solve next-generation data center design and operational challenges. QCT serves cloud service providers, telecoms and enterprises running public, hybrid and private clouds.
Product lines include hyperconverged and software-defined data center solutions as well as servers, storage, switches and integrated racks with an ecosystem of hardware components and software partners. QCT designs, manufactures, integrates and services its offerings via its own global network. The parent of QCT is Quanta Computer, Inc., a Fortune Global 500 corporation. www.QCT.io
AMD, the AMD arrow logo, EPYC, and combinations thereof are trademarks of Advanced Micro Devices, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210315005004/en/
Contact information
Yi-Chieh Lee (EMEA)
Yi-Chieh.Lee@qct.io
Daphne Wang
Daphne.wang@qct.io
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom